...
search icon
tbph-img

Theravance Biopharma Inc, Common Stock

TBPH

NMQ

$10.62

+$0.02

(0.19%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$530.51M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
162.05K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.08
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$7.44 L
$11.82 H
$10.62

About Theravance Biopharma Inc, Common Stock

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameTBPHSectorS&P500
1-Week Return0.09%-1.68%-0.63%
1-Month Return13.1%-0.67%0.46%
3-Month Return15.31%-9.11%6.48%
6-Month Return9.37%-2.8%1.89%
1-Year Return25.24%-8.53%8.94%
3-Year Return18.26%8.87%58.67%
5-Year Return-49.38%33.75%91.64%
10-Year Return-26.15%75.55%181.75%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue71.86M55.31M51.35M57.42M64.38M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":76.97,"profit":true},{"date":"2022-12-31","value":71.46,"profit":true},{"date":"2023-12-31","value":79.91,"profit":true},{"date":"2024-12-31","value":89.6,"profit":true}]
Cost of Revenue260.95M7.29M6.59M40.62M6.01M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.79,"profit":true},{"date":"2022-12-31","value":2.52,"profit":true},{"date":"2023-12-31","value":15.57,"profit":true},{"date":"2024-12-31","value":2.3,"profit":true}]
Gross Profit(189.10M)48.02M44.76M57.42M64.38M[{"date":"2020-12-31","value":-293.71,"profit":false},{"date":"2021-12-31","value":74.59,"profit":true},{"date":"2022-12-31","value":69.52,"profit":true},{"date":"2023-12-31","value":89.19,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(263.16%)86.83%87.17%100.00%100.00%[{"date":"2020-12-31","value":-263.16,"profit":false},{"date":"2021-12-31","value":86.83,"profit":true},{"date":"2022-12-31","value":87.17,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses369.61M292.95M130.47M113.46M111.33M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":79.26,"profit":true},{"date":"2022-12-31","value":35.3,"profit":true},{"date":"2023-12-31","value":30.7,"profit":true},{"date":"2024-12-31","value":30.12,"profit":true}]
Operating Income(297.76M)(257.78M)(91.96M)(56.03M)(46.95M)[{"date":"2020-12-31","value":-29775700000,"profit":false},{"date":"2021-12-31","value":-25778400000,"profit":false},{"date":"2022-12-31","value":-9195700000,"profit":false},{"date":"2023-12-31","value":-5603500000,"profit":false},{"date":"2024-12-31","value":-4694900000,"profit":false}]
Total Non-Operating Income/Expense(30.53M)(53.22M)1.32M15.48M4.67M[{"date":"2020-12-31","value":-197.25,"profit":false},{"date":"2021-12-31","value":-343.79,"profit":false},{"date":"2022-12-31","value":8.51,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":30.17,"profit":true}]
Pre-Tax Income(286.54M)(199.58M)(92.81M)(49.27M)(44.61M)[{"date":"2020-12-31","value":-28653700000,"profit":false},{"date":"2021-12-31","value":-19957700000,"profit":false},{"date":"2022-12-31","value":-9281500000,"profit":false},{"date":"2023-12-31","value":-4926900000,"profit":false},{"date":"2024-12-31","value":-4461400000,"profit":false}]
Income Taxes(8.52M)(151.00K)9.00K5.92M11.80M[{"date":"2020-12-31","value":-72.18,"profit":false},{"date":"2021-12-31","value":-1.28,"profit":false},{"date":"2022-12-31","value":0.08,"profit":true},{"date":"2023-12-31","value":50.19,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(278.02M)(199.43M)(92.82M)(55.19M)(56.42M)[{"date":"2020-12-31","value":-27801700000,"profit":false},{"date":"2021-12-31","value":-19942600000,"profit":false},{"date":"2022-12-31","value":-9282400000,"profit":false},{"date":"2023-12-31","value":-5519300000,"profit":false},{"date":"2024-12-31","value":-5641800000,"profit":false}]
Income From Continuous Operations(278.02M)(199.43M)(92.82M)(60.94M)(56.42M)[{"date":"2020-12-31","value":-27801700000,"profit":false},{"date":"2021-12-31","value":-19942600000,"profit":false},{"date":"2022-12-31","value":-9282400000,"profit":false},{"date":"2023-12-31","value":-6093900000,"profit":false},{"date":"2024-12-31","value":-5641800000,"profit":false}]
Income From Discontinued Operations16.81M65.64M964.96M--[{"date":"2020-12-31","value":1.74,"profit":true},{"date":"2021-12-31","value":6.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(278.02M)(199.43M)(92.82M)(55.19M)(56.42M)[{"date":"2020-12-31","value":-27801700000,"profit":false},{"date":"2021-12-31","value":-19942600000,"profit":false},{"date":"2022-12-31","value":-9282400000,"profit":false},{"date":"2023-12-31","value":-5519300000,"profit":false},{"date":"2024-12-31","value":-5641800000,"profit":false}]
EPS (Diluted)(4.48)(2.95)(0.67)(0.97)(0.63)[{"date":"2020-12-31","value":-448,"profit":false},{"date":"2021-12-31","value":-295,"profit":false},{"date":"2022-12-31","value":-67,"profit":false},{"date":"2023-12-31","value":-97,"profit":false},{"date":"2024-12-31","value":-62.91,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TBPH
Cash Ratio 4.15
Current Ratio 4.77

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TBPH
ROA (LTM) -7.98%
ROE (LTM) -31.46%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TBPH
Debt Ratio Lower is generally better. Negative is bad. 0.52
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.48

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TBPH
Trailing PE NM
Forward PE 526.32
P/S (TTM) 8.14
P/B 3.20
Price/FCF 12
EV/R 6.87
EV/Ebitda NM
PEG NM

FAQs

What is Theravance Biopharma Inc share price today?

Theravance Biopharma Inc (TBPH) share price today is $10.62

Can Indians buy Theravance Biopharma Inc shares?

Yes, Indians can buy shares of Theravance Biopharma Inc (TBPH) on Vested. To buy Theravance Biopharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TBPH stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Theravance Biopharma Inc be purchased?

Yes, you can purchase fractional shares of Theravance Biopharma Inc (TBPH) via the Vested app. You can start investing in Theravance Biopharma Inc (TBPH) with a minimum investment of $1.

How to invest in Theravance Biopharma Inc shares from India?

You can invest in shares of Theravance Biopharma Inc (TBPH) via Vested in three simple steps:

  • Click on Sign Up or Invest in TBPH stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Theravance Biopharma Inc shares
What is Theravance Biopharma Inc 52-week high and low stock price?

The 52-week high price of Theravance Biopharma Inc (TBPH) is $11.82. The 52-week low price of Theravance Biopharma Inc (TBPH) is $7.44.

What is Theravance Biopharma Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Theravance Biopharma Inc (TBPH) is 3.20

What is the Market Cap of Theravance Biopharma Inc?

The market capitalization of Theravance Biopharma Inc (TBPH) is $530.51M

What is Theravance Biopharma Inc’s stock symbol?

The stock symbol (or ticker) of Theravance Biopharma Inc is TBPH

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top